Abstract:Objective To study the risk factors and prognosis of immune checkpoint inhibitor-related pneumonitis ( ICI-P) and provide effective strategies for its prevention and treatment. Methods A retrospective investigation was conducted of the medical record of 753 non-small cell lung cancer cases treated with immune checkpoint inhibitors (ICIs) at Chinese PLA General Hospital from January 2018 to September 2023. According to whether or not ICI-P occurred, the patients were divided into ICI-P group (102 cases) and non-ICI-P group (651 cases), and the clinical characteristics of the two groups were compared. According to severity of ICI-P, the patients with ICI-P were divided into a mild group (69 cases) and severe group (33 cases), and survival analysis was performed for the two groups. t test, Mann-Whitney U test orχ2 test was used for comparison between groups. Logistic regression analyses were employed to determine the risk factors of ICI-P. Kaplan-Meier method was used to calculate the overall survival (OS) for the mild and severe groups, and Log-rank test was used to compare the survival of the two groups. Results The incidence of ICI-P was 13.5% (102/753). Its independent risk factors included interstitial lung disease (ILD) (OR=3.85,95%CI 1.99-7.46; P<0.001), history of chest radiotherapy (OR=2.65,95%CI 1.56-4.48; P<0.001), concurrent chest radiotherapy (OR=3.56,95%CI 1.69-7.47; P<0.001) and the use of programmed cell death 1 (PD-1) inhibitors (OR=3.54,95%CI 1.05-11.98; P=0.04). The expected OS of the mild group was 927 d against 573 d in the severe group, and the difference was statistically significant (P=0.033). Conclusion ILD, prior or concurrent chest radiotherapy and the use of PD-1 inhibitors are risk factors of ICI-P. Focusing on the assessment of patients with ILD and a history of chest radiotherapy before treatment and avoiding concurrent radiotherapy are feasible strategies for preventing ICI-P.